4/A: CEO Lewis Amends Stock Option Grant for Galectin Therapeutics

Galectin Therapeutics CEO Joel Lewis filed an amended Form 4 to correct the number of common stock options granted on January 16, 2026, to 91,000 at an exercise price of $3.04.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc. (GALT), filed an amended Form 4 to correct previously reported stock option information.
• The amendment clarifies that 91,000 common stock options were granted to Mr. Lewis on January 16, 2026.
• These options have an exercise price of $3.04 per share.
• The options vest in four equal installments: 25% on June 30, 2026, 25% on December 31, 2026, 25% on June 30, 2027, and 25% on December 31, 2027.
• The expiration date for these options is January 16, 2036.
• The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The filing is an administrative correction of an executive compensation detail, which is neutral in sentiment. The underlying grant of options is a standard practice for executive incentives.

Positives

• The grant of 91,000 stock options to President and CEO Joel Lewis aligns management's long-term interests with shareholder value creation.
• The company promptly corrected an administrative error in the initial filing, demonstrating transparency.

Negatives

• The necessity of filing an amendment indicates an initial administrative error in reporting the correct number of options granted.

Future Outlook

The vesting schedule for the granted stock options extends through December 31, 2027, indicating a long-term incentive structure for the CEO. The options themselves are exercisable until January 16, 2036.

Industry Context

The grant of stock options to executive leadership is a common practice in the biotechnology and pharmaceutical industry, including companies like Galectin Therapeutics, to incentivize performance and align management's financial interests with those of shareholders. Such compensation structures are standard for attracting and retaining key talent.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options represents potential future dilution if exercised, but also serves to align the CEO's interests with long-term shareholder value. The correction ensures accurate reporting of executive compensation.
• Management (Joel Lewis): Receives a significant equity incentive, tying personal financial success to the company's performance over the vesting period.

Next Steps

• The stock options will vest according to the specified schedule: 25% on June 30, 2026, 25% on December 31, 2026, 25% on June 30, 2027, and 25% on December 31, 2027.

Key Dates

Keywords

Galectin Therapeutics, GALT, Joel Lewis, stock options, Form 4/A, equity incentive plan, CEO compensation, insider transaction, amendment